Shares of direct-to-consumer telehealth business Hims & Hers Health are up 30% since the company reported its Q4 earnings . Here is why the company's performance is no fluke, and why investors can confidently buy this potential future multibagger . The company started with taboo conditions for men like erectile dysfunction and hair loss . It has roughly tripled its subscriber base to over 1.5 million over the past three years .